We recently reported an association between high levels of inflammation biomarkers and poor prognosis in mCRC, and this was particularly prominent in the subset of patients with BRAF-mutant tumours.22 Thus, in mCRC patients with BRAF-mutant tumour, unlike RAS-mutant or RAS/BRAF double wild-type tumours, high serum IL-6 predicted markedly impaired survival. The gene discussed is BRAF; the disease is neoplasm.